{"filings":[{"id":529197,"accession_number":"0001213900-26-059127","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2026-05-19T21:17:03+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxart files preliminary proxy; urges support for board nominees amid dissident challenge","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting set for July 16, 2026; preliminary proxy filed with SEC.","Dissident shareholder group nominated three candidates; company says they lack relevant biotech experience.","Cash resources ~$61M as of Q1 2026; funded runway into Q2 2027.","BARDA COVID-19 Phase 2b trial restored after stop-work order; main cohort primary readout expected early 2027.","CEO holds over 2.5M shares and has never sold a share; board added Dr. James Breitmeyer in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98521,"accession_number":"0001437749-26-015586","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxart reports Q1 net income $5.2M; COVID-19 sentinel data expected Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 net income $5.2M ($0.02/sh) vs net loss ($15.6M) in Q1 2025.","Revenue $39.2M (+87% YoY) mainly from BARDA contract and Dynavax license.","Cash $61.0M provides runway into Q2 2027; Lincoln Park equity facility up to $25M.","Topline sentinel data from Phase 2b COVID-19 trial (400 participants) anticipated in Q2 2026.","Appointed Dr. James B. Breitmeyer to board; relocated HQ to reduce overhead."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":39227000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98520,"accession_number":"0001437749-26-013195","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vaxart appoints Dr. James Breitmeyer to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. James Breitmeyer appointed to Vaxart Board effective April 23, 2026.","Brings over 35 years biopharma experience; led programs yielding 8 FDA product approvals.","Currently CEO and director of Altay Therapeutics; formerly President & CEO of Oncternal Therapeutics (2016-2025).","Prior roles include President of Bavarian Nordic (cancer/infectious disease vaccines) and senior clinical leadership at Eli Lilly and Cadence.","Will receive standard non-employee director cash and equity compensation under Vaxart's program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98519,"accession_number":"0001437749-26-012882","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vaxart expands Utah Avenue lease by 3,531 sq ft; HQ termination on schedule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment adds two suites totaling 3,531 rentable sq ft at Utah Avenue, South San Francisco.","Term of the new space is 36 months starting May 14, 2026.","Previously disclosed Harbor Way HQ lease termination remains effective May 15, 2026.","No financial terms of the amendment were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98518,"accession_number":"0001437749-26-012623","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Vaxart enters $25M equity purchase agreement with Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vaxart can sell up to $25M of common stock to Lincoln Park over 24 months at its discretion.","Lincoln Park is obligated to purchase shares at 97% of market price; no upper price limit.","Vaxart issued 447,067 commitment shares to Lincoln Park as consideration for the agreement.","No warrants, rights of first refusal, or participation rights; Lincoln Park barred from short sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114055,"accession_number":"0001437749-26-007968","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxart reports FY2025 net income of $16.3M vs loss; revenue $237.3M; cash runway into Q2 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $16.3M ($0.07 EPS) vs net loss $66.9M ($0.33 loss) in FY2024.","Revenue $237.3M, up from $28.7M, driven by BARDA contract and Dynavax collaboration.","Cash, equivalents & investments $63.8M; runway into Q2 2027.","COVID-19 Phase 2b sentinel cohort data (400 subjects) expected early Q2 2026; main cohort topline Q4 2026.","Published Phase 1 norovirus data shows passive antibody transfer to infants via breast milk; next trial dependent on partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130446,"accession_number":"0001437749-25-038774","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Vaxart terminates headquarters lease early; relocation to other South SF office","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease termination effective May 15, 2026, ~3 years early (original expiry March 31, 2029).","Premises: 24,606 sq ft at 170 Harbor Way, South San Francisco.","No termination fees or penalties payable to landlord.","Company to relocate headquarters and labs to another existing office in South SF area.","Termination part of ongoing cost reduction initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130445,"accession_number":"0001437749-25-034829","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxart reports Q3 revenue $72.4M, net loss $8.1M; signs Dynavax COVID-19 pill license deal worth up to $700M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $72.4M (vs $4.9M Q3 2024) from BARDA contract; net loss $8.1M ($0.04 EPS) vs $14.1M loss.","Exclusive license with Dynavax: $25M upfront + $5M equity; up to $700M in milestones and royalties.","Phase 2b COVID-19 trial enrollment completed (~5,400); topline data expected late 2026, sentinel cohort Q1 2026.","Cash, equivalents, investments $28.8M; with Dynavax payment runway extended to Q2 2027.","Phase 1 norovirus oral vaccine data shows robust fecal IgA; partnership discussions ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":133019000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130444,"accession_number":"0001437749-25-033362","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Vaxart signs exclusive license with Dynavax for oral COVID-19 vaccine; $25M upfront, $5M equity investment","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Dynavax pays $25M upfront license fee and $5M equity (11.1M shares at $0.45/share) for worldwide rights to Vaxart's oral COVID-19 vaccine.","Vaxart retains responsibility to complete ongoing Phase 2b trial (enrolled ~5,400; topline data expected late 2026) and EOP2 meeting.","After Phase 2b data, Dynavax can elect to assume development for $50M additional payment; otherwise agreement terminates.","If Dynavax continues, Vaxart eligible for up to $195M regulatory milestones, $425M sales milestones, and low-to-mid teens royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130443,"accession_number":"0001437749-25-030868","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"BARDA narrows Vaxart COVID vaccine pact; 5,000-subject follow-up continues","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Follow-Up Notice on Oct 8: BARDA intends to delimit Project Agreement excluding paused work.","Approximately 5,000 participants already enrolled in Phase 2b trial will continue to be followed.","Funding for follow-up of enrolled participants will continue; paused work no longer supported.","Company believes data from enrolled cohort will provide useful insights to advance COVID program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147008,"accession_number":"0001437749-25-029485","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Vaxart receives Nasdaq delisting notice after withdrawing reverse stock split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Sept 19, 2025, Nasdaq notified Vaxart that its securities will be delisted due to noncompliance with the Panel's conditions.","The company withdrew its reverse stock split proposal on Sept 18, 2025, failing a key condition for continued listing.","Trading on Nasdaq was suspended since July 8, 2025; VXRT now trades on OTCQX Best Market.","The Panel had required shareholder approval of a reverse split by Sept 5, 2025, and completion by Oct 6, 2025.","No further Nasdaq listing appeal is indicated; stock continues trading OTC under symbol VXRT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147007,"accession_number":"0001437749-25-029434","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vaxart withdraws proposal from stockholder consideration at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["On Sept 18, 2025, Vaxart withdrew the Proposal from stockholder consideration.","The special meeting was previously adjourned on Sept 5, 2025, and reconvened for Sept 19, 2025.","The Company will not reconvene the adjourned special meeting.","The Proposal was listed in the proxy statement filed Aug 6, 2025; details not disclosed in this filing.","No financial impact or further explanation provided in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147006,"accession_number":"0001437749-25-028570","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Vaxart adjourns special meeting to Sept 19; cites board changes and governance reviews","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting adjourned from Sept 5 to Sept 19, 2025 at 8:30 a.m. PT.","Board wants more time for stockholders to vote given recent board composition changes and potential governance disclosures.","Reverse stock split proposal was not voted on; company continues solicitation.","Record date remains July 29, 2025; new vote deadline is Sept 18, 2025 at 11:59 p.m. ET.","CEO emphasizes Nasdaq listing as key to advancing science and stockholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147005,"accession_number":"0001437749-25-028167","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vaxart Chairman Michael J. Finney to retire Sept 30, 2025; board reduced to 5 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Finney retires as Chairman and from Science & Technology Committee effective Sept 30, 2025.","Board size reduced from six to five directors upon Finney's departure.","Retirement is for personal reasons; no disagreement with Company operations or policies.","CEO Steven Lo thanked Finney for 16+ years of service; board to discuss leadership this month."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147004,"accession_number":"0001437749-25-028047","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vaxart granted Nasdaq extension; must complete reverse stock split by Oct 6, regain $1 bid price by Oct 17","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel decision on Aug 27, 2025 grants continued listing with three conditions.","Shareholder approval for reverse stock split required by Sep 5, 2025 special meeting.","Reverse stock split must be completed by Oct 6, 2025; bid price compliance by Oct 17, 2025.","Failure to obtain RSS approval will result in delisting per the Panel's decision.","Vaxart engaged in stockholder outreach; management emphasizes RSS vote for Nasdaq future."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147003,"accession_number":"0001437749-25-027524","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vaxart holds fireside chat; no material new information disclosed in furnished transcript","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Furnished transcript of virtual stockholder fireside chat on Aug 20, 2025.","Transcript includes only introductions and forward-looking statement caution; no financial or operational updates.","No earnings, guidance, clinical updates, or business milestones were discussed in the available portion.","Company ticker VXRT trades on OTCQX; no other tickers mentioned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147002,"accession_number":"0001437749-25-027110","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vaxart to hold stockholder fireside chat Aug 20 on reverse stock split; ISS, Glass Lewis back proposal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ISS and Glass Lewis recommend stockholders support the reverse stock split proposal.","Fireside chat on Aug 20, 2025 at 4:30 p.m. ET; management to explain rationale for split and Nasdaq compliance.","Reverse split intended to help regain Nasdaq listing; stock currently trades on OTCQX.","Stockholders of record as of July 29 must vote by 11:59 p.m. ET on Sep 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147001,"accession_number":"0001437749-25-026511","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxart Q2 rev $39.7M; norovirus antibodies up 141%; COVID trial stopped at 5K enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $39.7M (vs $6.4M YoY); net loss $15.0M ($0.07/sh) vs $16.5M ($0.09/sh).","Positive norovirus Phase 1: second-gen constructs raised GI.1 blockers 141%, GII.4 94% vs first-gen.","COVID-19 Phase 2b enrollment halted Aug 5 at ~5,000 of planned 10,000; follow-up continues through late 2026.","Cash $26.3M; runway into Q1 2026; exploring partnerships and non-dilutive funding to extend.","Special meeting Sep 5 to vote on reverse stock split (1:5 to 1:20) for Nasdaq compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":60606000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147000,"accession_number":"0001437749-25-024955","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["1.01","8.01"],"status":"ready","headline":"Vaxart receives stop work order from BARDA on Phase 2b oral COVID-19 vaccine trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATI/BARDA directed Vaxart to stop all work on Project Agreement RRPV-24-04-NGVx-003 for oral COVID-19 vaccine.","Company may only continue follow-up for already dosed participants in the 10,000-person cohort; enrollment about half complete.","No reason provided; DSMB had determined on July 14 that the study could proceed without modification.","Company expects a follow-up notice with further details; no additional funding or termination decision announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146999,"accession_number":"0001437749-25-022358","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxart delisted from Nasdaq, begins trading on OTCQX after bid price failure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq delisted VXRT for non-compliance with minimum bid price requirement (Rule 5550(a)(2)).","Trading suspended on Nasdaq July 8, 2025; stock began same-day trading on OTCQX Best Market under same ticker.","Vaxart appealed the delisting on July 3, 2025; shares remain suspended on Nasdaq pending hearing panel decision.","CEO Steven Lo says focus remains on advancing oral pill vaccine pipeline while considering listing options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146998,"accession_number":"0001437749-25-021865","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Vaxart receives Nasdaq delisting notice; trading suspended July 8, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Staff determined to delist VXRT common stock for failing to meet $1.00 minimum bid price requirement.","Trading will be suspended at open on July 8, 2025, despite planned hearing request.","Company expects to begin trading on OTC markets (ticker VXRT) on July 8, 2025, pending OTCQX approval.","Vaxart received prior notices on July 2, 2024, and Dec 31, 2024, regarding bid price non-compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.92,"calibrated_materiality_score":0.92,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165518,"accession_number":"0001437749-25-020651","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Vaxart shareholders reject reverse stock split and say-on-pay proposals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split amendment failed with 63.6M for, 91.9M against; company evaluating next steps.","Advisory say-on-pay proposal rejected: 34.4M for, 71.5M against, with 7.4M abstentions.","All six director nominees elected; David Wheadon received 46.5M for, 66.8M withheld.","Ratification of WithumSmith+Brown as auditor passed with 110.1M for, 38.0M against.","ATM facility in place with no shares sold as of June 13; special meeting on June 30 cancelled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165517,"accession_number":"0001437749-25-020040","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxart Phase 1 norovirus vaccine data: 141% (GI.1) and 94% (GII.4) antibody titer increases vs first-gen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second-gen constructs showed 141% increase in GI.1 and 94% increase in GII.4 NBAA titers vs first-gen at high dose, statistically significant.","All constructs safe and well-tolerated; no vaccine-related serious adverse events reported.","Vaxart plans Phase 2b as early as H2 2025, Phase 3 potentially in 2026, pending partnership/funding.","Company believes data supports potential for first-in-class or best-in-class oral norovirus vaccine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165516,"accession_number":"0001437749-25-019181","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Vaxart adjourns annual meeting to June 13 due to insufficient votes for reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Meeting adjourned from June 2 to June 13, 2025 at 8:30 a.m. PT to solicit more votes.","Proposal 2 (reverse stock split amendment) had insufficient votes; board continues to support it.","CEO says after discussions with large stockholders, many now intend to vote in favor.","ISS and Glass Lewis both recommend voting for Proposal 2.","Stockholders who haven't voted must do so by 11:59 p.m. ET on June 12; earlier voters may change vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165515,"accession_number":"0001437749-25-018648","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vaxart urges stockholders to vote FOR reverse stock split; Board commits to 1-for-20 high end","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting adjourned to June 2, 2025; vote deadline for reverse split is June 1, 2025.","Board committed to 1-for-20 high-end reverse split ratio, down from prior 1-for-50.","Proportional reduction in authorized shares will be proposed at a special meeting after the split.","Nasdaq compliance deadline is June 30, 2025; split is primary strategy to avoid delisting.","CEO Steven Lo disclosed new share purchases in the past month."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165514,"accession_number":"0001437749-25-018591","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxart doses first patient in 10,000-subject Phase 2b oral COVID-19 vaccine trial against mRNA comparator","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in 10,000-participant portion of Phase 2b trial for oral pill COVID-19 vaccine candidate.","Trial to assess relative efficacy, safety, and immunogenicity versus approved mRNA COVID-19 vaccine over 12 months.","DSMB reviewed 400-participant sentinel cohort safety data and recommended study proceed without modifications.","Project funded by BARDA/NIAID under Project NextGen with award valued up to $460.7 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165513,"accession_number":"0001437749-25-018021","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Vaxart adjourns annual meeting to June 2; seeks more votes for reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting adjourned to June 2, 2025 at 8:30 a.m. PT; proxies representing ~67% of shares already submitted.","Board urges approval of Proposal 2 (reverse stock split) to meet Nasdaq minimum bid price requirement.","Stockholders of record as of March 26, 2025 who haven't voted must do so by 11:59 p.m. ET on June 1.","Stockholders who previously voted against the reverse split can change their vote in favor.","Reasons cited: higher stock price may attract investors, analysts, and help retain employees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165512,"accession_number":"0001437749-25-017302","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxart narrows reverse split range to max 1-for-20; proposes proportional authorized share reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board narrowed proposed reverse split range: no ratio higher than 1-for-20.","If reverse split passes, authorized shares will be proportionally reduced at a future stockholder meeting.","Company urges stockholders to vote 'FOR' Proposal #2 by May 20, 2025, to avoid Nasdaq delisting.","Leading proxy advisors ISS and Glass Lewis support Proposal #2.","Proxy supplement filed; board cites stockholder input as reason for amendments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165511,"accession_number":"0001437749-25-016997","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxart gets BARDA approval to start dosing 10,000 participants in Phase 2b COVID vaccine trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["BARDA approved initiation of dosing in 10,000-participant Phase 2b trial of oral COVID-19 vaccine.","First patient expected to be dosed in Q2 2025, per CEO Steven Lo.","Trial is double-blind, randomized, comparator-controlled vs approved mRNA COVID-19 vaccine.","Funding under Project NextGen via RRPV Consortium valued at up to $460.7M.","Funding from HHS/ASPR/BARDA under Other Transaction 75A50123D00005."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165510,"accession_number":"0001437749-25-016500","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Vaxart appoints Jeroen Grasman as CFO, replaces Phillip Lee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Phillip Lee resigns effective upon appointment of successor; no disagreement; remains as non-executive employee through June 1, 2025.","Jeroen Grasman appointed CFO effective May 19, 2025; previously CFO at AltruBio, VP Finance at PACT Pharma and Genentech.","Grasman receives base salary $435K, target bonus 40%, option for 1M shares vesting over 48 months, RSU for 350K shares.","Lee forfeits unvested equity upon termination; no termination benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165509,"accession_number":"0001437749-25-016447","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxart Q1 net loss $15.6M; COVID-19 Phase 2b screening underway, CFO appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.6M ($0.07/shr) vs $24.4M ($0.14) prior year; revenue $20.9M from BARDA contract (vs $2.2M).","Cash $41.9M; runway into Q1 2026; Project NextGen award up to $460.7M, $85.6M received to date.","Screening for 10,000-person COVID-19 Phase 2b trial started; dosing expected Q2 2025 after stop work order lifted.","Norovirus Phase 1 enrollment complete (60 participants); topline data mid-2025; avian flu vaccine 100% protective in ferret model.","Jeroen Grasman appointed CFO effective May 19, 2025; Phillip Lee resigning as CFO for personal reasons."],"consensus_eps_estimate":0.0204,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":20876000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165508,"accession_number":"0001437749-25-015960","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxart addresses reverse split FAQs; vote May 21 to avoid Nasdaq delisting at $0.42/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stock closed at $0.42 on May 9, 2025, below Nasdaq's $1.00 minimum bid requirement.","Board proposes reverse split ratio of not less than 1:5 and not more than 1:50; intends to choose lowest ratio needed.","ISS and Glass Lewis recommend stockholders vote FOR the reverse split proposal.","Annual Meeting scheduled for May 21, 2025; management says split does not change fundamental value.","Board may not effect split if share price recovers above $1.00 before required deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165507,"accession_number":"0001437749-25-014405","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vaxart updates: BARDA stop-work lifted, norovirus enrollment done, reverse split proposal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BARDA stop-work order on COVID-19 Phase 2b trial lifted April 24, 2025; 10,000-participant portion pending BARDA approval.","Norovirus program: all 60 participants enrolled in under 2 months; topline data expected mid-2025.","Cost reductions including workforce cuts extended cash runway into 2026; seeking additional non-dilutive funding.","Annual meeting May 21, 2025; board seeks reverse stock split approval to avoid Nasdaq delisting; ISS and Glass Lewis recommend FOR.","Q1 2025 earnings call scheduled for May 13, 2025; webcast at Citizens Life Sciences Conference on May 7."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165506,"accession_number":"0001437749-25-013232","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["1.01","8.01"],"status":"ready","headline":"BARDA lifts stop work order on Vaxart norovirus trial; 10,000-participant screening to resume","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stop work order lifted April 24, 2025 by ATI/BARDA; company may resume incurring costs.","Virtual meeting with BARDA confirmed Vaxart can proceed with screening 10,000 participants.","Company intends to reactivate field sites and screen participants for enrollment.","Discussions with BARDA ongoing regarding dosing plan, costs, timelines, and regulatory pathway.","Previously all work except per-protocol follow-up for 400-person cohort had been halted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183157,"accession_number":"0001437749-25-008765","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Vaxart enters $50M at-the-market equity offering agreement with Citizens JMP and B. Riley","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may sell up to $50M of common stock at market prices via ATM facility.","Managers are Citizens JMP Securities and B. Riley Securities; placement fee is 3% of gross proceeds.","Sales may occur on Nasdaq or in negotiated transactions at company's instruction.","Company is not obligated to sell any shares and may terminate the agreement on three days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183156,"accession_number":"0001437749-25-008617","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Vaxart reports FY2024 net loss $66.9M, revenue $28.7M; initiates Phase 1 norovirus trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $66.9M ($0.33/sh) vs $82.5M in 2023; revenue $28.7M (up from $7.4M).","Cash $51.7M provides runway into Q4 2025; workforce reduced ~10% after COVID trial stop-work order.","Phase 1 trial of second-gen norovirus vaccine started; topline data expected mid-2025.","COVID-19 Phase 2b sentinel cohort enrolled; U.S. government stop-work order issued, only per-protocol follow-up allowed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183155,"accession_number":"0001437749-25-006907","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxart initiates Phase 1 trial for oral norovirus vaccine; topline data expected mid-2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Phase 1 open-label dose-ranging trial evaluating second-generation oral norovirus pill vaccine vs first-generation constructs.","Topline data expected as early as mid-2025.","If successful, Phase 2 could start H2 2025, Phase 3 as early as 2026, subject to partnership or other funding.","No vaccines currently approved for norovirus; Vaxart's oral pill is the only clinical-stage candidate.","CEO Steven Lo cites urgent public health need as norovirus spreads globally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183154,"accession_number":"0001437749-25-004824","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["1.01","8.01"],"status":"ready","headline":"Vaxart receives stop work order from BARDA on Project Agreement; work halted for 90 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received stop work order from ATI (BARDA) on Feb 21, 2025 for all efforts under Project Agreement RRPV-24-04-NGVx-003.","Exception: Company may continue per protocol follow-up for the 400-person cohort.","Stop work is effective for 90 days; ATI may cancel, extend, or terminate within that period.","Project Agreement dated June 13, 2024; no financial impact disclosed yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183153,"accession_number":"0001437749-25-003319","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Vaxart secures $105.9M BARDA funding increase; Phase 2b trial to test KP.2 vaccine vs mRNA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total BARDA funding for the Phase 2b trial now $240.1M, up from $134.2M.","Next trial portion will enroll 10,000 participants comparing Vaxart's KP.2 oral vaccine against an mRNA KP.2 comparator.","Sentinel cohort of 400 (XBB vs mRNA XBB) completed; DSMB recommended proceed without modification.","Vaxart awaiting BARDA approval to commence dosing in the KP.2 portion.","Funding increase supports manufacturing of new KP.2 lots and expanded clinical activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183152,"accession_number":"0001437749-25-001949","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vaxart appoints Kevin Finney to board; Robert Yedid resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin Finney appointed to Vaxart board effective Jan 28, 2025; will serve on Audit and Nominating/Governance committees.","Robert A. Yedid resigned from board on Jan 28, 2025 for personal reasons; no disagreement with the company.","Elaine J. Heron appointed to Compensation Committee effective Jan 28, 2025.","Finney is CEO/President of Autobahn Therapeutics and brings 35 years of biotech leadership experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183151,"accession_number":"0001437749-25-001459","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"DSMB recommends Vaxart's COVID-19 Phase 2b trial proceed; norovirus Phase 1 in H1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMB recommends Phase 2b proceed after review of 30-day safety data from 400-participant sentinel cohort.","Trial to enroll ~10,000 participants pending FDA review and BARDA approval.","Norovirus Phase 1 trial of second-gen vs first-gen constructs to start H1 2025, topline data mid-2025.","New avian influenza vaccine candidate (clade 2.3.4.4b) in preclinical studies.","Cash runway into 2026 supported by BARDA award of up to $460.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199730,"accession_number":"0001437749-24-038599","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2024-12-31T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Vaxart receives second 180-day Nasdaq extension to cure bid price deficiency until June 30, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Vaxart on Dec 31, 2024 of an additional 180-day compliance period to meet the $1.00 minimum bid price requirement.","Extension moves the cure deadline from Dec 30, 2024 to June 30, 2025.","Company is considering a reverse stock split as a potential cure for the deficiency.","If not compliant by June 30, 2025, Nasdaq will issue a delisting notice; Vaxart may appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199729,"accession_number":"0001437749-24-038436","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2024-12-27T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Vaxart secures $37.7M additional BARDA funding for oral COVID-19 vaccine trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Modification No. 4 increases allotted trial funding from ~$96.5M to ~$134.2M.","Additional $37.7M for mRNA comparator acquisition and clinical site readiness.","Total estimated ceiling raised by ~$4.6M to ~$460.7M.","Trial compares Vaxart's oral XBB COVID-19 vaccine to an FDA-approved mRNA vaccine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199728,"accession_number":"0001437749-24-036730","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxart completes sentinel cohort enrollment in Phase 2b oral COVID vaccine trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sentinel cohort of 400 participants randomized 1:1 to Vaxart's oral pill vaccine or approved mRNA comparator.","Last dose administered Nov 26, 2024; DSMB and FDA will review 30-day safety data before expanding.","Upon favorable review and BARDA approval, second part will enroll approximately 10,000 participants.","Project NextGen award (BARDA) valued at up to $456 million; trial includes >=25% over age 65.","Primary endpoint is relative efficacy vs mRNA comparator for prevention of symptomatic COVID-19 disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199727,"accession_number":"0001437749-24-034897","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxart Q3 net loss narrows to $14.1M; COVID Phase 2b sentinel enrollment near completion","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $4.9M (up from $2.1M YoY) from BARDA contracts; net loss per share $0.06 vs $0.11.","Cash $58.7M; expects runway into 2026; R&D $15.1M, G&A $4.3M.","Sentinel cohort enrollment of Phase 2b COVID vaccine trial expected to complete Nov 2024; 10,000-participant phase could start early 2025 if safety data favorable.","FDA requested new clinical data for norovirus program; Vaxart created more potent GI.1 and GII.4 constructs.","Preclinical data on HPV mucosal vaccine published in Vaccines in August 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":13515000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199726,"accession_number":"0001437749-24-030878","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Vaxart terminates at-the-market equity offering agreement with Cantor, B. Riley","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Termination effective October 18, 2024; no termination penalties incurred.","From Sept 2021 to Oct 2024, Vaxart sold 17.5M shares for ~$28.6M gross proceeds under the ATM.","After termination, Vaxart may not offer or sell additional shares under the Sales Agreement.","No reason for termination disclosed; may signal a shift in capital-raising strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215747,"accession_number":"0001437749-24-030276","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Vaxart initiates sentinel cohort of Phase 2b oral COVID-19 vaccine trial; BARDA raises funding to $456M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Modification No. 3 increased total estimated ceiling to ~$456.1M (+$3.2M) and allotted funding to ~$96.5M (+$30.8M).","Sentinel cohort of 400 participants (200 Vaxart oral pill, 200 mRNA comparator) begins; 30-day safety data will trigger enrollment of 10,000.","Trial will measure efficacy against symptomatic/asymptomatic disease, systemic and mucosal immunity, and safety.","Funding via Project NextGen (BARDA); full Phase 2b primary efficacy analysis at 12 months post-vaccination.","Vaxart's XBB vaccine construct and newly funded KP.2-targeting construct are part of the study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215746,"accession_number":"0001437749-24-025539","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxart Q2 net loss narrows to $16.5M; BARDA award up to $453M for COVID Phase 2b","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $0.09 vs $0.16 YoY; revenue $6.4M (from $1.4M) on BARDA contract.","Cash and investments $62.6M at June 30; received ~$64.7M BARDA payment post-quarter.","BARDA Project NextGen award up to $453M to support 10,000-subject Phase 2b COVID trial vs mRNA comparator.","Enrollment for Phase 2b expected in H2 2024 pending FDA alignment; cash runway into 2026.","Norovirus vaccine: in discussions with FDA on correlates of protection; evaluating Phase 2b/challenge study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":8582000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215745,"accession_number":"0001437749-24-022250","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Vaxart receives Nasdaq notice of non-compliance with $1.00 minimum bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received July 2, 2024; bid price below $1.00 for 30 consecutive days (May 17–July 1, 2024).","Company has 180 calendar days, until Dec 30, 2024, to regain compliance by closing at $1.00 for 10 straight days.","If not cured, may seek additional 180-day period by meeting other listing requirements and indicating intent to reverse split.","Company monitoring bid price and evaluating options; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235149,"accession_number":"0001437749-24-020779","cik":72444,"company_name":"Vaxart, Inc.","ticker":"VXRT","form_type":"8-K/A","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vaxart corrects vote count for share-increase proposal; outcome unchanged","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Corrected voting tabulation error for Proposal 2 to increase authorized shares from 250M to 350M.","Revised results: 35,936,013 For, 21,134,398 Against, 491,543 Abstain, 47,701,989 Broker non-votes.","Proposal still approved despite correction; no change to outcome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":147600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-06-20T23:59:59+00:00|235149"}